Results 121 to 130 of about 112,380 (305)

Cuproptosis and Mitophagy Mediated by the THUMPD1/IGF2R‐Dependent Suppression of AKT and Activation of AMPK Signaling Suppress Lung Adenocarcinoma Progression

Advanced Science, EarlyView.
THUMPD1 drives a tumor‐suppressive signaling cascade in lung adenocarcinoma by promoting IGF2R expression. IGF2R associates with PPP2R1A to suppress AKT and activate AMPK, leading to SLC31A1 upregulation and copper accumulation. Elevated copper disrupts mitochondrial metabolism and induces excessive mitophagy, thereby restraining tumor growth and ...
Kai Wu, Bo Qin, Zhuoyu Gu, Weizheng Ding, Xiaoming Chen, Kaishang Zhang, Yujin Qiao, Shuang Yuan, Song Zhao, Xiangnan Li, Peng Zhang   +10 more
wiley   +1 more source

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging

EJNMMI Radiopharmacy and Chemistry
Background Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a promising class of therapeutics, particularly in the treatment of cancers with defective DNA repair mechanisms, such as those with breast cancer genes (BRCA) mutations.
Gianluca Destro, Rebecca Rizzo, Chiara Rua, Raha Rouhbakhsh Azimi, Silvia Morbelli   +4 more
doaj   +1 more source

PARP inhibitors for prostate cancer

Seminars in Oncology
Poly(ADP-ribose) polymerase (PARP) inhibitors have transformed the treatment landscape for patients with metastatic castration-resistant prostate cancer (mCRPC) and alterations in DNA damage response genes. This has also led to widespread use of genomic testing in all patients with mCRPC.
Ossian Longoria, Nick Beije, Johann S. de Bono   +2 more
openaire   +2 more sources

Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer

Advanced Science, EarlyView.
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen, Dingru Li, Yingna Liao, Zehua Wang, Chunbin Zhu, Zifeng Zhang, Liquan Jin, Yueyue Chen, Jiaoshun Chen, Junyi Xu, Miaoyan Wei, Rong Tang, Xianjun Yu, Si Shi   +13 more
wiley   +1 more source

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review

Diagnostics, 2019
Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved drugs designed to exploit synthetic lethality, and were first introduced as a cancer-targeting strategy in 2005. They have led to a major change in the treatment of advanced
Stergios Boussios, Peeter Karihtala, Michele Moschetta, Afroditi Karathanasi, Agne Sadauskaite, Elie Rassy, Nicholas Pavlidis   +6 more
doaj   +1 more source

Biomarkers of PARP inhibitor sensitivity

Breast Cancer Research and Treatment, 2011
The PARP inhibitors represent one of the most exciting recent developments in cancer therapy. Substantial efficacy has been shown with PARP inhibitors in the treatment of hereditary BRCA1/2 related Breast and Ovarian cancer as single agents [1–3] and in combination with temozolomide [4].
Turner, Nicholas C., Ashworth, Alan
openaire   +3 more sources

Detachment‐Induced FAK‐STAT3‐NNMT Inhibits CTCs Anoikis to Promote Breast Cancer Metastasis by Enhancing Fatty Acid Oxidation

Advanced Science, EarlyView.
The FAK‐STAT3‐NNMT axis drives anoikis resistance in circulating tumor cells by reprogramming fatty acid oxidation. Targeting this metabolic vulnerability suppresses metastasis, untangling a key mechanism of breast cancer progression and revealing NNMT as a promising therapeutic target.
Qingchao Tong, Yilei Ma, Yuzhen Gao, Lin Zhou, Luping Lou, Qiang Fang, Sining Fang, Ru Zhao, Jin Zeng, Jun Yang, Guoli Li, Xinyou Xie, Yanzhong Wang, Jun Zhang   +13 more
wiley   +1 more source

Piezo1 Channel Mediates Mechanically Programmable Drug Delivery to Potentiate Intravesical Chemotherapy

Advanced Science, EarlyView.
This study utilizes programmable mechanical pressure as a therapeutic enhancer to establish a mechano‐chemotherapy strategy. Controlled pressure activates the mechanosensitive ion channel Piezo1 in bladder cancer, triggering a calcium ion cascade that transiently and reversibly amplifies membrane permeability to chemotherapeutics.
Minghai Ma, Xing Li, Minxuan Jing, Zezhong Yang, Jiale He, Jianpeng Li, Xiao Liang, Yunzhong Jiang, Rou Huang, Yuanquan Zhang, Yuanchun Pu, Jiawei Xiu, Yutong Chen, Kaibo Mi, Pu Zhang, Lei Wang, Jinhai Fan   +16 more
wiley   +1 more source

Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials

Frontiers in Pharmacology
BackgroundThe landscape of poly (ADP-ribose) polymerase (PARP) inhibitor treatment for ovarian cancer (OC) is continually evolving. This research aimed to evaluate the efficacy and safety of PARP inhibitors compared to placebo as a maintenance therapy ...
Guojuan Sun, Yi Liu
doaj   +1 more source

A Single‐Enzyme Activated CRISPR‐Cas12a Nano System via Subtly Balanced dsDNA for Kinetic‐Gated UDG Detection and Spatiotemporal Cellular Imaging

Advanced Science, EarlyView.
Kinetic‐gated CRISPR–Cas12a activation enables single‐enzyme detection and spatiotemporal imaging of UDG ABSTRACT Uracil‐DNA glycosylase (UDG) is a key enzyme in base excision repair and an important biomarker for genomic stability and disease. In many reported sensing systems, uracil excision is coupled to signal generation through additional ...
Kejun Dong, Hao Hu, Haiyun Wang, Zijia Zheng, Shuangshuang Cheng, Wan Shu, Ruisi Liu, Xiaoyan Xin, Shiyi Huang, Dingchao Qian, Xianjin Xiao, Qiang Fu, Hongbo Wang   +12 more
wiley   +1 more source